In the article, “Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy” by Serebruany et al, which appeared in the August 26, 2003, issue of the journal (Circulation. 2003;108:939–944), some information was inadvertently omitted from the conflict-of-interest disclosure footnote. The following disclosures are added:
Dr Califf has received research support from and served as a consultant for Pfizer (all proceeds donated to Duke University). Dr O’Connor has received research support from and has consulted for Pfizer, GlaxoSmithKline, Eli Lilly, and Forest Pharmaceuticals, and holds patents for selective serotonin reuptake inhibitor research.